ArticleScientific reports2017
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.International journal of molecular sciences · 2023Pooled it
- The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma.Cancer gene therapy · 2024Article
- Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas.Cancers · 2023Article
- Current and Emerging Medical Therapies in Pituitary Tumors.Journal of clinical medicine · 2022Review
- CRHR1 mediates the transcriptional expression of pituitary hormones and their receptors under hypoxia.Frontiers in endocrinology · 2022Article
- Resilience in Long-Term Viral Infection: Genetic Determinants and Interactions.International journal of molecular sciences · 2021Article
- Article
- Article
- Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.Frontiers in endocrinology · 2021Review
- Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.Journal of endocrinological investigation · 2020Review
- Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.Cancers · 2019Article
- Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety.Molecules (Basel, Switzerland) · 2019Review
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.Pharmacological reviews · 2018Review
- Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.Scientific reports · 2018Article
- New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 10 institutions in 2 countries.
Alejandro Ibáñez-CostaMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Laura M López-SánchezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Manuel D GaheteMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Esther Rivero-CortésMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Mari C Vázquez-BorregoMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
María A GálvezMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Andrés de la RivaMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Eva Venegas-MorenoMetabolism and Nutrition Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), 41013 Seville, Spain.
Luis Jiménez-ReinaDepartment of Morphological Sciences, University of Cordoba, 14004 Cordoba, Spain.
Alberto Moreno-CarazoEndocrinology and Nutrition Unit, Complejo Hospitalario de Jaén, 23007 Jaén, Spain.
Francisco J TinahonesService of Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain.
Silvia Maraver-SelfaService of Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de la Victoria, 29010 Málaga, Spain.
Miguel A JapónDepartment of Pathology, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.
Juan A García-ArnésDepartment of Endocrinology and Nutrition, Carlos Haya Hospital, 29010 Málaga, Spain.
Alfonso Soto-MorenoMetabolism and Nutrition Unit, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), 41013 Seville, Spain.
Susan M WebbDepartment of Endocrinology, Hospital Sant Pau, Centre for Biomedical Research on Rare Diseases (Centro de Investigación Biomédica en Red de Enfermedades Raras Unit 747) Autonomous University of Barcelona; 08035 Barcelona Spain.
Rhonda D KinemanDepartment of Medicine, University of Illinois at Chicago, Jesse Brown Veterans Affairs Medical Center, Research and Development Division, Chicago, Illinois, USA.
Michael D CullerIPSEN Bioscience, Cambridge, 02142 Massachusetts, USA.
Justo P CastañoMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Raúl M LuqueMaimonides Institute of Biomedical Research of Cordoba (IMIBIC); 14004 Cordoba, Spain.
Instituto Maimónides de Investigación Biomédica de Córdoba · ESHospital Clínico Universitario Virgen de la Victoria · ESInstituto de Biomedicina de Sevilla · ESUniversity of Córdoba · ESCentre for Biomedical Network Research on Rare Diseases · ESComplejo Hospitalario de Jaén · ESCordoba University · USHospital Doctor José Molina Orosa · ESHospital Universitario Virgen del Rocío · ESUniversity of Illinois Chicago · US
Funding
Growth hormone and adult physiologyR01DK088133 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KINEMAN, RHONDA D · 2010 to 2013
$1.0MMouse model of adult-onset, isolated, GH-deficiencyR21AG031465 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KINEMAN, RHONDA D · 2008 to 2009
$284kNIA NIH HHS R21 AG031465NIDDK NIH HHS R01 DK088133
Abstract
Chimeric somatostatin/dopamine compounds such as BIM-23A760, an sst2/sst5/D
Indexed as
AdenomaAdolescentAdultAgedAnimalsApoptosisCalcium SignalingCells, CulturedCell SurvivalDopamineDopamine AgonistsExocytosisFemaleHumansMaleMiddle AgedDopamineDopamine AgonistsReceptors, DopamineReceptors, SomatostatinSomatostatinTBR-760
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.